Bajaj Healthcare surges on launching antiviral drug `Favijaj`
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Bajaj Healthcare is currently trading at Rs. 597.50, up by 14.45 points or 2.48% from its previous closing of Rs. 583.05 on the BSE.
The scrip opened at Rs. 614.40 and has touched a high and low of Rs. 619.00 and Rs. 552.65 respectively. So far 149195 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 619.00 on 05-May-2021 and a 52 week low of Rs. 238.05 on 11-May-2020.
Last one week high and low of the scrip stood at Rs. 619.00 and Rs. 475.00 respectively. The current market cap of the company is Rs. 798.70 crore.
The promoters holding in the company stood at 67.26%, Non-Institutions held 32.74%.
Bajaj Healthcare has launched ‘Favijaj’ (Favipiravir) an antiviral drug used for treating patients suffering from influenza virus and has proved to be effective over COVID patients. The company has received approval from India's drug regulator, to manufacture and market ‘Favijaj’ the oral Favipiravir approved medication in India for the treatment of COVID-19 from May 04, 2021.
‘Favijaj’tablets comprising Favipiravir in different dosage forms is used for the treatment of mild to moderate Covid-19 disease. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus.
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
